tBID-Mediated Apoptosis in the Cumulus–Oocyte Complex of Endometriosis: Protective Role of Nanocurcumin

Endometriosis is a chronic gynecological disorder characterized by ectopic endometrial growth, inflammation, and mitochondrial dysfunction within the cumulus–oocyte complex (COC), leading to impaired oocyte competence. Truncated BID (tBID) plays a central role in linking extrinsic and intrinsic apoptotic pathways, and its dysregulation contributes to mitochondrial-mediated apoptosis in endometriosis. Curcumin possesses anti-inflammatory and anti-apoptotic properties; however, its limited bioavailability may be enhanced through nanoparticle formulation as nanocurcumin. This study aimed to evaluate the effect of nanocurcumin on tBID expression in an experimental endometriosis model. Thirty-one female Mus musculus were randomly assigned into four groups: positive control (C+) and three treatment groups receiving oral nanocurcumin at 2.5 mg/kgBW (T1), 5 mg/kgBW (T2), and 10 mg/kgBW (T3) for 14 days. Ovarian tissues were collected, and tBID expression in granulosa cells was assessed by immunohistochemistry and semi-quantified using the Immunoreactive Score (IRS). All animals developed endometriosis features. Nanocurcumin treatment significantly reduced tBID expression compared with the control group (p < 0.05), with the lowest expression observed in T3 (IRS 1.57 ± 0.26). Post hoc analysis demonstrated a dose-dependent reduction, with T3 differing significantly from T1 and the control. These findings indicate that nanocurcumin downregulates tBID expression, suggesting attenuation of mitochondrial-mediated apoptosis and potential preservation of oocyte quality in endometriosis. This study supports the therapeutic potential of nanocurcumin as a non-hormonal adjuvant for endometriosis, in line with Sustainable Development Goal 3 (Good Health and Well-being), particularly in addressing reproductive health challenges in women.   Keywords: Endometriosis, Nanocurcumin, Truncated BID, Cumulus–Oocyte Complex, Good Health and Well-being.

Authors

Institutions

Publication Details

Journal
Tropical Journal of Natural Product Research
Published
2026-04-01
DOI
https://doi.org/10.26538/tjnpr/v10i3.32
Primary Topic
Endometriosis Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

tBID-Mediated Apoptosis in the Cumulus–Oocyte Complex of Endometriosis: Protective Role of Nanocurcumin

Hendy Hendarto, Widjiati Widjiati, Muhammad Y.A Widyanugraha
Tropical Journal of Natural Product Research
Endometriosis Research and Treatment
article

tBID-Mediated Apoptosis in the Cumulus–Oocyte Complex of Endometriosis: Protective Role of Nanocurcumin

Hendy Hendarto, Widjiati Widjiati, Muhammad Y.A Widyanugraha
article en

Abstract

Endometriosis is a chronic gynecological disorder characterized by ectopic endometrial growth, inflammation, and mitochondrial dysfunction within the cumulus–oocyte complex (COC), leading to impaired oocyte competence. Truncated BID (tBID) plays a central role in linking extrinsic and intrinsic apoptotic pathways, and its dysregulation contributes to mitochondrial-mediated apoptosis in endometriosis. Curcumin possesses anti-inflammatory and anti-apoptotic properties; however, its limited bioavailability may be enhanced through nanoparticle formulation as nanocurcumin. This study aimed to evaluate the effect of nanocurcumin on tBID expression in an experimental endometriosis model. Thirty-one female Mus musculus were randomly assigned into four groups: positive control (C+) and three treatment groups receiving oral nanocurcumin at 2.5 mg/kgBW (T1), 5 mg/kgBW (T2), and 10 mg/kgBW (T3) for 14 days. Ovarian tissues were collected, and tBID expression in granulosa cells was assessed by immunohistochemistry and semi-quantified using the Immunoreactive Score (IRS). All animals developed endometriosis features. Nanocurcumin treatment significantly reduced tBID expression compared with the control group (p < 0.05), with the lowest expression observed in T3 (IRS 1.57 ± 0.26). Post hoc analysis demonstrated a dose-dependent reduction, with T3 differing significantly from T1 and the control. These findings indicate that nanocurcumin downregulates tBID expression, suggesting attenuation of mitochondrial-mediated apoptosis and potential preservation of oocyte quality in endometriosis. This study supports the therapeutic potential of nanocurcumin as a non-hormonal adjuvant for endometriosis, in line with Sustainable Development Goal 3 (Good Health and Well-being), particularly in addressing reproductive health challenges in women.   Keywords: Endometriosis, Nanocurcumin, Truncated BID, Cumulus–Oocyte Complex, Good Health and Well-being.

Tropical Journal of Natural Product ResearchVol. 10(3)
Universitas Airlangga (ID)
Openalex Percentile: Top 13%
Endometriosis Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.